CALIXAR offers a unique and patented technological platform allowing to isolate in solution – with the highest purity levels – full-length membrane proteins, while keeping their structural and functional integrity. Our approach represents the opportunity for pharmaceutical companies to start and work with high quality targets or antigens before developing antibodies, formulating vaccines and/or discovering a primary lead through Structure Based Drug Design or High Throughput Screening assays.
CALIXAR Best Inventing French-Tech Company 2018
CALIXAR named best inventor 2018 of the French Auvergne-Rhône Region among French-Tech start-up companies.
16 May 2018
New Review on Membrane Proteins
New review on the solubilization and stabilization for wild-type and full-length membrane proteins.
22 March 2018
CALIXAR and ASTRAZENECA to publish new insight on KCC2 architecture and function in Scientific Reports
28 November 2017